REGN

Business Context and Reporting Period

Company: Regeneron Pharmaceuticals, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2002
Business Overview: Regeneron is a biopharmaceutical company focused on discovering, developing, and commercializing therapeutic drugs for serious medical conditions. The company has not yet generated revenue from the commercialization of its own product candidates. Its primary revenue sources are contract research and development (R&D) and contract manufacturing agreements with partners such as Merck & Co., Inc., The Procter & Gamble Company, and Amgen-Regeneron Partners.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Total revenue decreased 22% to $4.9 million. Contract R&D revenue dropped due to the completion of studies for Amgen-Regeneron Partners. Contract manufacturing revenue declined due to reduced shipments of vaccine intermediates to Merck.
• Expense Increase: Total operating expenses rose 43% to $30.1 million. R&D expenses increased 52% to $25.5 million, driven by the expansion of the Phase III clinical program for AXOKINE (obesity treatment) and increased staffing.
• Interest Expense Surge: Interest expense jumped from $47,000 to $3.0 million due to the issuance of $200 million in convertible senior subordinated notes in October 2001 (5.5% interest rate).
• Investment Income: Remained stable at $2.8 million for both periods.
• Cash Flow: Net cash used in operating activities increased to $26.1 million from $8.4 million. Investing activities used $86.9 million, primarily for the purchase of marketable securities and capital expenditures.

Guidance, Outlook, and Risks

Management Commentary and Outlook

• Clinical Pipeline: The company is heavily investing in its Phase III program for AXOKINE (obesity), which enrolled approximately 2,000 patients in a pivotal trial. Additional trials for shorter dosing periods were initiated in April 2002. Positive preliminary results were reported for the IL1 Trap (rheumatoid arthritis) in Phase I, with Phase II expected in mid-2002.
• Capital Requirements: Management anticipates R&D expenses will increase by more than 30% in 2002. Approximately $50 million in capital expenditures is expected for the remainder of 2002 for manufacturing and R&D expansion.
• Liquidity: With $409.4 million in cash and marketable securities, management believes current resources will fund operations through at least 2003. No established lines of credit exist.

Risks and Contingencies

• Development Risk: No assurance that product candidates (AXOKINE, IL1 Trap, VEGF Trap) will prove safe, effective, or receive regulatory approval.
• Immune Response: Recombinant proteins may trigger antibody formation in patients, potentially neutralizing the drug's effectiveness.
• Collaboration Dependence: Termination of agreements with partners like Procter & Gamble or Amgen could materially impact funding.
• Financing: Future funding may be required; there is no guarantee additional financing will be available on acceptable terms.

Investor Verification Checklist

• AXOKINE Phase III Progress: Verify enrollment status and preliminary data readouts for the pivotal obesity trial.
• Burn Rate vs. Cash Reserves: Confirm if the projected 30%+ increase in R&D spending aligns with the $409.4 million cash runway through 2003.
• Convertible Note Terms: Review the specific conversion price ($30.25) and dilution impact of the $200 million debt issued in late 2001.
• Merck Manufacturing Volume: Monitor shipment volumes of the vaccine intermediate to understand the volatility in contract manufacturing revenue.
• Patent Portfolio: Assess the status of intellectual property filings, given the significant increase in patent-related G&A expenses.